Boehringer Ingelheim USA Corporation

Top 5 oncology biosimilar articles in 2024: Duke's CGT biosimilar recommendations, FDA approval of Henlius' Hercessi, biosimilar business updates (BI layoffs, Teva-mAbxience partnership), rituximab biosimilar CT-P10 safety for SLE, and FDA approval of Coherus' Neulasta Onpro biosimilar.

Top 5 IPF articles of 2024 include oxygen therapy's impact on fibrosing ILD, delayed diagnoses linked to worse outcomes, nerandomilast's success in FIBRONEER-IPF trial, diabetes' effect on pulmonary fibrosis, and increased macrophage research since 2020.

The FDA approved three immunotherapy drugs for resectable NSCLC without clear evidence on their benefits before or after surgery. Oncologists face dilemmas in treatment decisions due to lack of data on when immunotherapy is most effective. Recent discussions suggest neoadjuvant therapy may offer more benefits than adjuvant, potentially reducing unnecessary treatments and risks.

Asia Deal Watch: Kaken acquires Aadi subsidiary and cancer drug Fyarro. Other deals include Hangzhou DAC/Aadi, Astellas/Sangamo, Kyorin/Bayer, Eisai/Newron, Lupin/Boehringer Ingelheim, Asahi Kasei/Chiome.

Boehringer Ingelheim and Eli Lilly's Jardiance may prevent worsening of diabetic eye disease in type 2 diabetes patients, per JAMA Ophthalmology. Analysis of over 80,000 patients showed Jardiance users had 22% lower risk of existing diabetic eye disease worsening compared to DPP4 inhibitor users. The study suggests Jardiance's potential benefit in managing diabetic retinopathy.

Rising ACR20 response rates in placebo arms of rheumatoid arthritis trials may be linked to global recruitment shifts, with recent trials including more patients from less affluent countries.

Durvalumab improved progression-free survival (PFS) over placebo in patients with locally advanced, unresectable non–small cell lung cancer (NSCLC) after platinum-based chemoradiotherapy (CRT), with a 25% reduction in risk of disease progression or death. Subgroup analysis showed consistent PFS benefit regardless of CRT type, and a trend toward improved overall survival (OS) was observed. PACIFIC-5 supports consolidation immunotherapy after either concurrent or sequential CRT.

Anaveon appoints Richard Sachse, M.D., Ph.D., as Chief Medical Officer starting February 1, 2025. With over 25 years in biopharma, Sachse's expertise will aid in advancing Anaveon's oncology programs, including ANV600. He succeeds Eduard Gasal, M.D., who contributed significantly to Anaveon's clinical development.

Klick Health welcomes new senior leaders, emphasizing innovation and client-focused solutions in healthcare communications. The agency's unique model and commitment to excellence attract top talent, aiming to disrupt the status quo and deliver impactful, forward-thinking solutions across diverse therapeutic areas and regions.

The schizophrenia market in 7MM is projected to grow at a 7.4% CAGR, from $8.4b in 2021 to $17b in 2031, driven by 11 late-stage pipeline products. These therapies are expected to capture 33.4% of the market share in 2031, with Cobenfy projected to be the top-selling drug by 2031, with $2.2b in sales. However, patent expirations of LAIs may slow growth, though new therapies will help counterbalance this.